[Our experiences of anal squamous cell carcinoma treated by chemoradiotherapy].

We reviewed the clinical records of 6 cases with anal squamous cell carcinoma to evaluate the clinical effectiveness of chemoradiotherapy (CRT). The radiotherapy consisted of 40 Gy delivered to the pelvis and bilateral inguinal lesion, and a perianal booster dose of 20 Gy, in fractions of 2.0 Gy per day, 5 days per week. 5-FU and mitomycin C were administrated 3 times every 4 weeks as standard chemotherapy. On the first day of radiation therapy, 750 mg/m2 of 5-FU in the form of a continuous 24-hour infusion for 5 days was given. On the first day of chemotherapy, 10 mg/m2 of mitomycin C was also given as a single bolus infusion. One aged patient with a T3 tumor was administrated oral S-1 during radiotherapy. Four patients had a T2 tumor, 1 had a T1 tumor, and 1 had a T3 tumor. One patient had metastases in the Virchow lymph node that originated from synchronous vaginal cancer. No patient had hematogenous metastases. Grade 2 adverse effects occurred in 3 patients, and Grade 3 in 1 patient, during CRT, but the completion of CRT was achieved in all 6 patients. All patients had complete response (CR) in the anal lesion after CRT. Only the patient with a T3 tumor who was administrated S- 1 showed signs of recurrence in the anal lesion. CRT is expected to be a safe and effective treatment for improving the prognosis of anal squamous carcinoma.